Lesogaberan: GABAB receptor agonist treatment of gastroesophageal reflux disease

Brian E. Lacy, Robert Chehade, Michael D. Crowell

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


(Chemical Equation Presented) Gastroesophageal reflux disease (GERD) is a highly prevalent medical disorder. Most patients require chronic medical therapy and proton pump inhibitors (PPIs) are the mainstay of treatment. Some patients, however, have persistent symptoms of reflux despite PPI therapy. A medication to treat the major pathophysiologic event that causes reflux, transient lower esophageal sphincter relaxations (TLESRs), could improve reflux symptoms and potentially reduce complications of persistent acid reflux. Baclofen, a GABAB receptor agonist, has been shown to reduce TLESRs and acid reflux in both healthy volunteers and patients with GERD. Central nervous system (CNS) side effects limited its use in clinical practice. Lesogaberan is a novel, peripherally acting, GABAB receptor agonist with limited CNS side effects that decreases TLESRs, reduces the number of acid reflux events and improves acid exposure time in the distal esophagus. This monograph will review the pharmacology, preclinical and clinical data, and discuss the safety of this new compound.

Original languageEnglish (US)
Pages (from-to)987-992
Number of pages6
JournalDrugs of the Future
Issue number12
StatePublished - Dec 2010

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Lesogaberan: GABAB receptor agonist treatment of gastroesophageal reflux disease'. Together they form a unique fingerprint.

Cite this